Alpha-1 Antitrypsin Deficiency Treatment Market Research Report - Forecast till 2027

Alpha-1 Antitrypsin Deficiency Treatment Market Research Report: By Drugs (Alpha-1 Proteinase Inhibitor,  Bronchodilators, Steroids), Route of Administration (Oral, Intravenous, Inhalation) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) - Forecast to 2027

ID: MRFR/HC/6847-HCR | February 2021 | Region: Global | 111 pages

Alpha-1 Antitrypsin Deficiency Treatment Market Forecast


Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.


Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.


Market Synopsis


Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the alpha-1 antitrypsin deficiency treatment market.


Strategic mergers & acquisitions are also projected to boost alpha-1 antitrypsin deficiency treatment market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.


High unmet medical needs in developing economies are directly providing lucrative opportunities for the alpha-1 antitrypsin deficiency treatment market growth.


Market Influencers


The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.


Market Drivers



  • Increasing prevalence of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency or AATD is a genetic disease that may cause severe lung or liver disfunction. The prevalence of alpha-1 antitrypsin deficiency is increasing, which is resulting in market growth. 1 in 1500 to 3500 Europeans are affected by AATD. Since the prevalence of AATD is increasing, the demand for treatment of AATD is also increasing, which is resulting in the positive growth of the alpha-1 antitrypsin deficiency treatment market.

  • Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs

  • Rising awareness regarding alpha-1 antitrypsin deficiency

  • High unmet medical needs in developing economies

  • Increasing R&D expenditure by key players to develop innovative treatment options for AATD


Market Restraints



  • Stringent government regulatory policies

  • High cost of drugs


Segmentation


By Drugs



  • Alpha-1 Proteinase Inhibitor: This drug type is expected to hold the largest market share. In April 2019, CSL Behring received FDA approval for Zemaira, which is alpha-1 proteinase inhibitor. So, the rising number of product approvals is expected to drive the alpha-1 antitrypsin deficiency treatment market growth.

  • Bronchodilators: Used for prevention from upper respiratory tract infections.

  • Steroids: Consists of corticosteroids used for the treatment of COPD associated with AATD.

  • Others: Consists of oxygen therapy, antibiotics, and other drugs used for the treatment of complications associated with AATD, such as jaundiced skin, breathing problems, etc.


By Route of Administration



  • Oral: This route of administration is expected to hold the largest alpha-1 antitrypsin deficiency treatment market share due to its high usage.

  • Intravenous: This drug type is expected to grow at the fastest rate owing to the ease of administration.

  • Inhalation: This route of administration is mainly used for administration of corticosteroids and drugs for the treatment of breathing disorders associated with AATD.

  • Others: Consists of subcutaneous and intramuscular routes of administration.


By Distribution Channel



  • Hospital Pharmacy: The segment holds the largest market size as the treatment is mostly carried out in hospitals.

  • Retail Pharmacy: They provide prescriptions that are intended to be used at home.

  • Online Stores: Fastest growing segment owing to the increasing number of online pharmacy stores.


By Region



  • Americas: The largest regional market. The high patient population suffering from alpha-1 antitrypsin deficiency is expected to drive the alpha-1 antitrypsin deficiency treatment market growth. Approximately 1 in 2,500 Americans suffer from the disease. This serves to drive the growth of the alpha-1 antitrypsin deficiency treatment market in the region.

  • Europe: Europe has some of the best healthcare services in the world. Increasing prevalence and the developed healthcare industry are driving the alpha-1 antitrypsin deficiency treatment market growth.

  • Asia-Pacific: The fastest-growing regional market for alpha-1 antitrypsin deficiency treatment, Asia-Pacific has the world’s largest population and fast-developing healthcare industry which is anticipated to drive the market growth.

  • Middle East & Africa: The alpha-1 antitrypsin deficiency treatment market growth is attributed to the developing healthcare industry in regions such as Saudi Arabia, Oman, and Qatar.


Key Players



  • Kamada Pharmaceuticals (Israel): Offers Glassia, an alpha-1 antitrypsin deficiency treatment drug. It also has inhalation AATD drug in Phase 2 clinical trials in the US and phase 3 clinical trials in Europe.

  • CSL Behring LLC (US): Leading provider of plasma-derived and recombinant therapeutic products for rare diseases such as AATD. Hosted the symposium about AATD treatment in Paris.

  • Grifols, S.A. (Spain): Offers the Grifols Prolastin -C Liquid (alpha-1 proteinase inhibitor) for the treatment of AATD since 2017.

  • Takeda Pharmaceutical Company Limited (Japan): Manufactures drugs for emphysema which is a main form of AATD.

  • GlaxoSmithKline plc (UK): The company offers bronchodilators for the treatment of AATD.

  • Boehringer Ingelheim GmbH (Germany): Manufacturer and distributor for bronchodilators.

  • AstraZeneca (UK): Offers bronchodilators such as the Bevespi Aerosphere inhalation aerosol for treatment of COPD associated with AATD.

  • Vectura Group plc (UK): Offers Ultibro Breezhaler dual bronchodilator.

  • Pfizer Inc. (US): Offers the Spiriva Handihaler bronchodilator for the treatment of COPD associated with AATD.

  • Mylan Inc. (US): Received FDA approval in November 2018 for YUPELRI, a long-acting muscarinic antagonist nebulized bronchodilator.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 2,914.7 Million
  • 2027: Significant Value
  •   CAGR   10.50% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drugs, Route of Administration, Distribution Channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Kamada Pharmaceuticals (Israel), CSL Behring LLC (US), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany), AstraZeneca (UK), Vectura Group plc (UK), Pfizer Inc. (US), Mylan Inc. (US)
      Key Market Opportunities   Increasing R&D expenditure by key players to develop innovative treatment options for AATD
      Key Market Drivers

  • Increasing prevalence of alpha-1 antitrypsin deficiency
  • Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs
  • Rising awareness regarding alpha-1 antitrypsin deficiency
  • High unmet medical needs in developing economies


  • Frequently Asked Questions (FAQ) :


    The Alpha-1 Antitrypsin Deficiency Treatment Market was valued at USD 1.4 billion in 2018.

    Alpha-1 Antitrypsin Deficiency Treatment Market is expected to exhibit a strong 10.5% CAGR over the forecast period from 2019 to 2025.

    Growing awareness about the condition of alpha-1 antitrypsin deficiency is likely to be the major driver for the market.

    The Americas dominate the Alpha-1 Antitrypsin Deficiency Treatment Market.

    Leading players in the Alpha-1 Antitrypsin Deficiency Treatment Market include Kamada, Pfizer, and Mylan, among others.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.